Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells[1]
References
[1] Caroline Thue Hvilsom, et al. TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure. Front Immunol. 2021 Sep 23;12:704617. DOI:10.3389/fimmu.2021.704617
